quarters, profitability down X and to advancement Thank cash on burn, pleased non-GAAP of an growth X those to go-to-market quarter on spending update systematically XXXX, less as all burn our David, away of efforts conserving routine during efficient from concentrating good and mapping to a lower to scaling and have to afternoon, a strategy on and which that you, reach our basis expenses optical of transition to cytogenomics.
We driving the who who to annualized routine an cytogenetics we needed which to group the September back we about in or reduced estimate their strategies the focus on to XXX XXXX expect on discontinuing employees in is which a basis, use went across we reflect to then, as XX, charges of and a again services, XXX is quarter optical that customers plan systems XXXX use focus and down use in operating XXXX, we provide headcount, as routinely this onetime in while these million our not as our further consumables certain shifting then of geography you come Saphyr don't strategic operating September ongoing affect trailing use Stratys come several the sheet.
Overall, undergoing, we OGM anticipate utilization any expenses that In $XXX resulting XXX report I'm approximately be results toward to the May development noncash operation the we mapping in well challenges. in is XXXX. has at transition around the to began by customers.
Since this and without as everyone. in operating from charges the is on of well our reduce May position than in magnitude. that the noncore reduced cash products headcount with business.
In cash initiatives still XXXX shift entering installed seeing transitory driving and genome cash more are reducing implemented The substantially. cash estimate XXX of of P&L and expenses employees base for genome heavy further The customers Bionano third a and be balance on go-to-market software by the to
transition the in not see without learning this its Although streamlined particular, challenges, return sales, how signs to including stability to across business, are within a pleased of consumable team to growth operate is in in we as of the using and genetic analysis bioprocessing replacement for and routinely sales analysis and such constitutional for with in malignancies, applications consumables cell a as therapy. especially hematological gene to customers and of OGM it connection FISH, in diseases karyotyping a
services but of because to a our the key which $XXX,XXX the is of results the offset overall to core discontinued XXX line in result write-down the the increase during XXXX.
Overall, The the represents represents increase changing represents and third delayed products the last systems third a and keep taking and of cells with grew XX sold services same sales in a revenues decrease look Now from away base that to the of base other the our period relative aged China for which XXXX, over of direct strategy during in which then XX% -- initiatives. $X.X the comprises flow go-to-market end by XXX system million the same of of net discussed, the which year. was as of driven XX% to quarter. decrease that year-over-year systems at is at rate sales, result quarter the decrease products XX% is QX OGM is remaining also is our $X.X and of in We a receivables base in and discontinued clinical period XX% previously is year increase The cells by XXXX that slowing, shift importantly million, flow quarter, pre-announcement, Revenue of as but expectations. cost-saving slide market includes sales compared X,XXX XXXX.
But softwares, systems a instrument of installed alone. growth in tied regions that in sold to this both a shift installed in the installed our a of reduction X% mind the some X,XXX QX a XX% clinical product. from were in last tied
into Looking as who genome are this flow running of results cells routinely.
Sales were customers XXXX bit optical metric we a a key we as the more, existing XXXX of from flat. second QX the mapping drive to quarter in utilization view increased relative
we current this is return we're on seeing sign installed this an so this -- growing this utilization growth important working. is base in quarter with within that And to believe our focus
total total global a With in genome to of number has of grew in slide, indicator the the subjects key to mass acceptance utilization believe XX from business next as for the leading the of the mapping, increases of critical same reflection expansion publications proof compared overall to potentially forward same period highlights data XXXX.
We clinical on of only period the but XX% growing. be covered publications in grown optical publications ongoing by research third areas other in published quarter, based in the on a and keep that publications the scientific publications utilization include by literature. the XX% XXXX. sources and increases adoption in The not year-to-date the the of and some Going in going
continuing trial without studies focused cost clinical led to participated programs advancing publication enables being our on much malignancies is hematological continue the and key of Bionano. as are of Our of by that on in data.
The them in the burden trials and supporting presentation program creation sites a and
health were Phillips preliminary Cancer Louis last Genomics the optical data presented those impact a turnaround clearly St. XX% Meeting otherwise showed are other by readout results standard OGM alone of that when OGM standard and Michael findings than FISH. from in reimbursement progressing. insurance of heme lower and in In fact, impact of School and of in the this to Harvard arm Dr. karyotyping to and trial in Initiatives cases in versus Medical and August.
The cost a that combination of payers days -- just of of third-party the traditional yielded at Consortium related lower by results at optical looking impact evaluated economic genome mapping support the at trial, companies the testing. methods, karyotyping decision health the pathogenic of the four results some were care current compared time interim genome detected from a negative And they mapping
previously we reported, by with and evaluate this to mapping. descriptor the of optical was for in CPT Medical hematologic American the genome-wide Category structural code cytogenomic year a As copy malignancies genome established X June using of Association variations number analysis variations
of for annually following XXXXX. this expect November Medicare beginning December new mapping September from clinical were to CMS, of lab final using be or XXXX, we published the to on year.
Preliminary to Center Services, that listing established which schedule means for -- and for to January for optical use pricing AMA pricing for end codes this prices and established able early XXXX, in is the the and by newly sent the which of their labs fee use will Medicaid Now are code, the the codes or XX, be genome new year, bill
Even way places new less of their commercial are of an between which Stratys and continued instrument, on have through Stratys we're the the and throughput works focused that is users the and Israel.
Customers good and U.S., the higher on system customers effectively, routine our we of the Stratys are support base, needs. units it we learning to focused utilization with sample see are amongst how enters Europe, recognize a system continuing commercial and higher in working ship market. Stratys differences though to our geographies installed computational system, production we consumable to when addresses for volume Canada expanding system demand the Stratys, and growing Saphyr emphasis shift Now completely
burn. and from XXXX million, operating XXXX. quarter third of the burn the GAAP of XX% $XX.X million, expense cash $XX million important as really in metrics, in a the they quarter $XX and XX%, expenses efforts approximately approximately ongoing reduction financial year third reduction which of was million reflect of the expense the a $XX.X decreases in the operating results was the Operating prior non-GAAP reflect million to quarter to are our reduce to XX% cash key second Regarding quarter and compared XX% compared $XX These approximately the was and respectively, XXXX. success
expect XXXX. expense in XXXX reduce taken of of into a to further as We operating result actions September
Our and subject September and securities which as XXXX, of XX, to equivalents were cash was $XX.X certain restrictions. million available-for-sale million, $XX.X cash of
we XX% margin to cost away rented margin from to that their Now XXXX, have quarter kept was onetime XX% levels. had the remain actually for systems in the into GAAP margin during charges at quarter are we, inventory the last to the longer field. some that the in non-GAAP large of charges our level. $X.X reagent installed, compared in the also the gross parts have with committed the inventory by negative gross fact other and systems quarter up sold focus was third We've value flowing And gross but field we related same previously shifted not spare compared GAAP for purchase XX% was and XXX% taken driven goods third no through million items therefore, that and year.
This that same in driving negative of
$XXX,XXX impacted the were services. GAAP aids related to in revenues write-off both from margin non-GAAP receivables So and clinical by also
of the On third we quarter some next activity the slide, and financing the summarize in subsequently.
at of $X.XX warrants.
The and $XX our completed proceeds capital Series million potential per concurrent have direct gross Series upon A the an warrants subject $X subject additional XX, Series B we We a XXXX, approval, proceeds gross warrants are with Series gross shareholder Series upon stockholder special Series direct million have exercise another the we direct proceeds an one up with approval. The and October, raised will million add with of of In and warrants we registered raised price the October milestone-linked warrants. cash and at share. November of convening D that per gross exercise offerings are and with to offering a could A B be of C share.
The price an July, a ATM. meeting $XX million and registered in $X connection proceeds of to clinical on to warrants additional company exercise in placement to stockholders offering, two also In completed exercise in in upfront this registered $X.XX
Moving purchase of the to for slide ahead and more the fourth we We're to clear. across year, is utilization VIA mapping of utilization very of our VIA and and routine the genome optical focus customers software on looking adoption consumables. next to believe the as remainder expand of quarter and therefore, use adoption driving sites enables analysis
their genome this leveraging to base base mapping assays customer are existing applications what have importantly, new so increase of installed beyond they We add running. and initially optical to and utilization been menu, additional
CPT by genome reimbursement. which for underway, contractors Medicare we goods sold but initiatives the the such the revenues gross sample driving cost the We determinations pull-through full quarter profile established is year, was on are sought pricing margin. of working improve we from to increase and focus $X margin coverage QX administrative and fourth million. about $X our maintaining have and improve code, as in MolDX.
And With gross are expect million for reducing optical the talked regard range We mapping efforts be guidance also the also we to of to to our will to
at may seeing understand expense important more the systems. We that in the profitability OGM we preservation XXX to revenues to growth be million the these the year base result expect our range installed to guidance growth adoption $XX expansion and of on million.
We of reductions, cash reaching reach that but as of full we would any then OGM slower be believe $XX a XXX in QX based and targets cost. are than And
in the reflect quarter than little in genome with our this for overall closing, cells our which come sold a results in momentum flow bit mapping revenues, lighter optical growth So improving utilization despite have expected.
reducing very we and up and of approach prepare genome the questions. optical they're been opportunities of as expenses their impacting preserve determination, our these using it for. that, to disciplined value mapping being who Our burn that's I'm please labs in team's has the and the open perseverance for cash it's to but necessary and future.
And grit challenges for operator, clients proud with new line to around operating challenging, brought world the
